Bayer, Vidac Pharma, BioNTech - Healthcare sector on the verge of a renaissance

Bayer - Positive study results

Bayer is still struggling with the legal disputes surrounding the expensive Monsanto takeover. In addition to the claims for damages, the resulting debts are weighing heavily on the Company. The Company is also facing challenges in oncology research. The start of the Phase III study "SOHO-2" for its potential lung cancer drug BAY2927088 is an important step. To date, there are no approved first-line targeted therapies for non-small cell lung cancer (NSCLC) with HER2 mutations. A successful trial is crucial for Bayer to strengthen the credibility of its pipeline and ensure long-term success in oncology. Competitive pressure and strict regulatory requirements present additional hurdles.

Despite the challenges in the oncology field, Bayer is showing promising developments in its Pharmaceuticals division. The drug candidate Kerendia, already approved for treating chronic kidney disease in type 2 diabetes, could soon also be used for heart failure. Impressive results were presented at the ESC Cardiology Congress in London. The studies show a significant reduction in deaths and hospitalizations of 16% compared to placebo. This could enable an extension of the approval and secure Bayer a strong position in the cardiovascular drug market.

Analysts see great potential in Bayer's recent advancements. The revenue increases achieved with Kerendia in the second quarter of this year underscore this: between April and June, Bayer recorded a 72% increase in revenue, reaching EUR 115 million. These figures reinforce investors' confidence in Bayer's ability to advance its pharmaceutical division despite existing challenges. If the approval of the extension remains successful, Kerendia could help to compensate for the lost revenue from other drugs with expiring patents. Analysts are forecasting peak annual sales of over EUR 2 billion for the drug. Bayer shares continue to trend sideways and are currently trading at EUR 28.15.

Vidac Pharma - Technical report causes a stir

Vidac Pharma, a listed company in the clinical development phase, offers an exciting and promising prospect. Vidac Pharma's latest product, VDA-1275, is at the center of interest following a technical report. This innovative drug candidate for the treatment of solid tumors has achieved impressive results in preclinical studies. As a monotherapy, VDA-1275 shows significant anti-tumor efficacy. Even more remarkable are the synergistic effects observed when VDA-1275 is used in combination with conventional cancer therapies. Another positive aspect is the ability of VDA-1275 to trigger an immune response - a promising indication of its potential in cancer treatment.

The key findings of the study were that VDA-1275 restarts apoptosis (programmed cell death), stops the rapid proliferation of cancer cells, reduces the hyperglycolytic metabolism typical of tumors, triggers an immunological response, increases survival in a colon cancer model in mice in a statistically significant way, and shows a synergistic effect in combination with widely used anti-cancer drugs in a 3D organoid model of human liver cancer. The first human clinical trials are planned for Q1 2025. These tests mark a crucial step in the development of VDA-1275 and could catapult Vidac Pharma into a new era of cancer treatment options.

Another promising product in the pipeline, VDA-1102, is already in Phase II clinical trials. This drug has already shown positive results in the treatment of actinic keratosis. In addition, regulatory authorities in Austria and Israel have given the green light for Phase II trials for the treatment of mycosis fungoides, a form of cutaneous T-cell lymphoma. In view of the progress made and the upcoming clinical trials, there is great potential here. The analysts at Sphene Capital issued a "Buy" recommendation with a target price of EUR 4.90 on July 29. The share is currently trading at EUR 0.25 in Stuttgart.

BioNTech - From highs to challenges

During the turbulent times of the COVID-19 pandemic, the biotech industry experienced an unprecedented boom, particularly due to the successful launch of mRNA vaccines. BioNTech was in the spotlight, posting record share prices and high profits. However, as the pandemic threat receded, the demand for vaccines also fell dramatically. The Company came under pressure to diversify its business models. However, the Mainz-based company does not yet have another product ready for series production and is, therefore, currently struggling with considerable losses and is forced to develop long-term growth strategies.

After the pandemic, BioNTech increasingly focused on its roots: the development of cancer drugs. The Company is working on innovative therapies for infectious diseases such as malaria and tuberculosis as well as mRNA-based cancer vaccines. The hope is to use these technologies as successfully as with COVID-19. BioNTech's Chief Medical Officer Özlem Türeci recently stated that cancer therapy in the future will be personalized and targeted, with mRNA vaccines, antibody-drug conjugates, and cell therapies playing an important role.

Despite the current losses and legal battles, such as patent disputes and demands for higher royalties, there are also bright spots. Successful research programs and the potential launch of new drugs could stabilize the share in the long term. Analysts expect a moderate recovery in the share price. Recent advances in oncology, combined with a focus on personalized medicine and targeted therapies, offer promising, albeit risky, investment potential in a changing biotechnology landscape. The share has now moved well away from the EUR 70 mark and is currently trading at EUR 78.85.

Overall, everything points to a promising future for the healthcare sector. Despite challenges, Bayer is showing progress in the pharma sector, especially with Kerendia, which is showing significant clinical success. Vidac Pharma is achieving promising results in preclinical and clinical trials with innovative drugs such as VDA-1275 and VDA-1102 and is fully committed to the fight against cancer. BioNTech, on the other hand, is working hard to diversify its businesses, particularly in the field of cancer treatment**, to ensure long-term stability and growth. These developments point to a flourishing renaissance in the healthcare sector.